Convergen (Suzhou) Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a serine/threonine-protein kinase PAK4-targeting moiety through a linker reported to be useful for the treatment of cancer.
Hainan Simcere Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising a glycoengineered antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
The receptor tyrosine kinase-like orphan 1 (ROR1) is a transmembrane protein expressed during embryonic development. Moreover, it is highly expressed on the surface of several cancer cell types, including B-cell malignancies and solid tumors such as triple-negative breast cancer (TNBC). Researchers from The University of Queensland and collaborating institutions recently reported the development of a single-chain fragment variable (scFvs) specifically targeting the membrane proximal region of ROR1 rather than the Ig-like domain, aiming to reduce cross-reactivity with other surface proteins expressed in normal tissues.
Shanghai Henlius Biotech Inc. has announced acceptance of IND applications by China’s National Medical Products Administration (NMPA) for three differentiated candidates for the treatment of solid tumors.
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Hutchmed (China) Ltd. has moved closer to establishing China’s first domestically developed FGFR-targeted therapy for intrahepatic cholangiocarcinoma, after the National Medical Products Administration (NMPA) accepted its NDA for fanregratinib (HMPL-453) and granted the drug priority review.
Guangzhou Institutes of Biomedicine and Health has disclosed bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of diabetes, autoimmune diseases, cardiovascular disorders, male contraception, chronic obstructive pulmonary disease, viral and parasitic infections and cancer.
Venetoclax has shown good results for adult acute myeloid leukemia (AML) in combination with azacitidine, but there is increasing evidence of inherent and acquired resistance. High expression of nicotinamide phosphoribosyltransferase (NAMPT) has been associated with cancer aggressiveness and poor prognosis due to increased nicotinamide metabolism.
Previous work showed that histone ‘readers’, which bind to post-translational modifications on histones, may be upregulated in melanoma and thereby upregulate oncogenes. Given that the histone reader ATAD2 is known to be overexpressed in several types of cancer, researchers at the University of Alabama at Birmingham asked whether the same is true in melanoma.
RSS
